ESPR 250117 4.50P (ESPR250117P4500) Stock Options, News & Quotes

US OptionsDetailed Quotes

ESPR250117P4500

Watchlist

2.25
+0.67+42.41%

15min DelayClose Dec 23 16:00 ET

2.25High2.25Low

Intraday

5D
Daily

News

Esperion Therapeutics Completes Financing Deals to Partially Repay Convertible Debt
MT NewswiresDec 18 08:34 ET
Express News | Esperion Strengthens Balance Sheet With Closing of Significant Refinancing Transactions
ReutersDec 18 07:00 ET
Goldman Sachs Upgrades Esperion Therapeutics(ESPR.US) to Hold Rating, Raises Target Price to $4
Moomoo NewsDec 18 01:31 ET · Ratings
Cantor Fitzgerald Initiates Esperion Therapeutics(ESPR.US) With Buy Rating, Announces Target Price $8
Moomoo NewsDec 17 17:31 ET · Ratings
Cantor Fitzgerald Initiates Esperion Therapeutics at Overweight With $8 Price Target
MT NewswiresDec 17 07:36 ET · Ratings
12 Health Care Stocks Moving In Friday's Pre-Market Session
BenzingaDec 13 16:06 ET

Comments

Youngman

Yesterday 19:51

New investors incoming!

$Esperion Therapeutics (ESPR.US)$Public Employees Retirement System of Ohio Acquires New Stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Youngman

Yesterday 04:56

$Esperion Therapeutics (ESPR.US)$ So guys what are we thinking for Monday? Is it Rocket 🚀 time?🤔

StockAmateur

Dec 20 13:56

$Esperion Therapeutics (ESPR.US)$ this stock needs a good news catalyst in order to jump high

Youngman

Dec 20 09:34

$Esperion Therapeutics (ESPR.US)$ Seven bullish signals. Let's go Bulls 🤑

10xStockPicks

Dec 20 00:13

Top Investment Idea, Cantor Starts This $2 Stock With $8 Target Overweight Rating, HCW Reiterates $16 Target.

$Esperion Therapeutics (ESPR.US)$Esperion initiated with an Overweight at Cantor Fitzgerald - TipRanks.com BELOW is a Detailed research report that should convince readers to have a portion of their investment portfolio in Esperion. This is not a pump article, please take the time to read and fact check. This $2 stock will be $20+ by 2027. Esperion anticipates Billions in Revenues.
Es...